Bio News

The CRISPR system, of which two classes and 46 subtypes have been identified to date, has been found to act as a “commander in chief” that regulates other immune genes in Neisseria bacteria. Under normal conditions, the CRISPR-Cas complex suppresses the expression of other defense genes, but when CRISPR is disabled by infection with a virus (phage), the suppression is lifted and a backup defense system is activated. The discovery is expected to contribute to the development of phage therapies that kill antibiotic-resistant bacteria and to the enhancement of industrial bacterial strains.

BIOBOOK TEAM
biobookmedia@biobook.co.krIonkura Reports 20.8-Month Median Survival in Phase 1 Trial for Metastatic Eye Cancer
Verastem’s VS-7375 Shows Response Rates of Up to 50% in Pancreatic Cancer; Phase 3 Trial to Begin This Year
Pfizer to Co-Develop Sec61 Inhibitors With Enodia in Deal Worth Up to $500 Million
Galderma to Acquire ZO Skin Health for $1.5 Billion, Expanding Dermatology Portfolio
Verdiva halts GLP-1 transition trial, citing ‘market changes’
Stryker to Invest $400 Million in CMR Surgical, Expand Robotic Surgery